Carlo, M. I., Molina, A. M., Lakhman, Y., Patil, S., Woo, K., DeLuca, J., . . . H. Voss, M. (2016). A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. Oncologist.
Citación estilo ChicagoCarlo, Maria I., et al. "A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma." Oncologist 2016.
Cita MLACarlo, Maria I., et al. "A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma." Oncologist 2016.